Anergis Preps for Pivotal Trial of Allergy Vaccine, Seeks Partner
LONDON – Anergis SA released new immunological data from the Phase IIb study of its lead product Allert, proving the synthetic allergy vaccine acts in the same way as traditional desensitizing allergy treatments and providing a comfort factor for potential pharma partners as licensing discussions progress.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter